(Albany, US) DelveInsight has launched a new report on “Helicobacter Pylori Infections – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Helicobacter Pylori Infections – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Helicobacter Pylori Infections, historical and forecasted epidemiology as well as the Helicobacter Pylori Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
Request for free sample report: https://www.delveinsight.com/sample-request/helicobacter-pylori-h-pylori-infection-market
Scope of the Report
Helicobacter Pylori Infections is a common type of bacteria that grows in the digestive tract and has a tendency to attack the stomach lining. It infects the stomachs of roughly 60 percent of the world’s adult population. H. pylori infections are usually harmless, but they’re responsible for the majority of ulcers in the stomach and small intestine. The “H” in the name is short for Helicobacter. “Helico” means spiral, which indicates that the bacteria are spiral shaped.
Symptoms
The symptoms associated with Helicobacter Pylori Infections include:
Causes
It’s still not known exactly how H. pylori infections spread. The bacteria have coexisted with humans for many thousands of years. The infections are thought to spread from one person’s mouth to another. They may also be transferred from feces to the mouth. This can happen when a person does not wash their hands thoroughly after using the bathroom. H. pylori can also spread through contact with contaminated water or food.
Complications
H. pylori infections can lead to peptic ulcers, but the infection or the ulcer itself can lead to more serious complications.
These include:
Treatment
Lowering stomach acid helps the antibiotics work more effectively. This treatment is sometimes referred to astriple therapy. Some of the drugs that are used in a triple therapy treatment include: clarithromycin, proton-pump inhibitors (PPI), such as lansoprazole (Prevacid), esomeprazole (Nexium), pantoprazole (Protonix), or rabeprazole (AcipHex), metronidazole (for 7 to 14 days), amoxicillin (for 7 to 14 days).
Some of the Companies:
Drugs Covered:
And Many Others
Table of Contents:
1. Key Insights
2. Executive Summary of Helicobacter Pylori Infections
3. Competitive Intelligence Analysis for Helicobacter Pylori Infections
4. Helicobacter Pylori Infections: Market Overview at a Glance
4.1. Helicobacter Pylori Infections Total Market Share (%) Distribution in 2017
4.2. Helicobacter Pylori Infections Total Market Share (%) Distribution in 2030
5. Helicobacter Pylori Infections: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Helicobacter Pylori Infections Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Helicobacter Pylori Infections Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Helicobacter Pylori Infections Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Helicobacter Pylori Infections Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Helicobacter Pylori Infections Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Helicobacter Pylori Infections Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Helicobacter Pylori Infections Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Helicobacter Pylori Infections Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Helicobacter Pylori Infections Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Helicobacter Pylori Infections Treatment and Management
8.2. Helicobacter Pylori Infections Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Helicobacter Pylori Infections Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Helicobacter Pylori Infections: Seven Major Market Analysis
13.1. Key Findings
13.2. Helicobacter Pylori Infections Market Size in 7MM
13.3. Helicobacter Pylori Infections Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Helicobacter Pylori Infections Total Market Size in the United States
15.1.2. Helicobacter Pylori Infections Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Helicobacter Pylori Infections Total Market Size in Germany
15.3.2. Helicobacter Pylori Infections Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Helicobacter Pylori Infections Total Market Size in France
15.4.2. Helicobacter Pylori Infections Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Helicobacter Pylori Infections Total Market Size in Italy
15.5.2. Helicobacter Pylori Infections Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Helicobacter Pylori Infections Total Market Size in Spain
15.6.2. Helicobacter Pylori Infections Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Helicobacter Pylori Infections Total Market Size in the United Kingdom
15.7.2. Helicobacter Pylori Infections Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Helicobacter Pylori Infections Total Market Size in Japan
15.8.3. Helicobacter Pylori Infections Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Helicobacter Pylori Infections
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/helicobacter-pylori-h-pylori-infection-market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market